Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02011113 · MORE INFO

Limitations, agreements, and source contact

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma · Source last updated 2016-11-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
Disclosure agreements varied; the Investigators shall not disclose any material/information disclosed by the Sponsor (Celgene KK) with the clinical trial or information obtained by conducting the clinical trial to third parties without Sponsor's prior written approval.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrialDisclosure@Celgene.com
organization
Celgene Corporation
phone
888-260-1599
title
Anne McClain, Senior Manager
Complete source fields
certain Agreement
other Details
Disclosure agreements varied; the Investigators shall not disclose any material/information disclosed by the Sponsor (Celgene KK) with the clinical trial or information obtained by conducting the clinical trial to third parties without Sponsor's prior written approval.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrialDisclosure@Celgene.com
organization
Celgene Corporation
phone
888-260-1599
title
Anne McClain, Senior Manager

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice